Streetbeat News

Products Services

MODG

Topgolf is set to open a new venue in Greensboro, North Carolina, on September 13, 2024. This will be the fourth Topgolf location in the state, joining others in Charlotte and Durham.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:12 pm

OTRK

Ontrak, Inc. (NASDAQ:OTRK) has partnered with MosaicVoice to enhance healthcare delivery and patient outcomes using AI-powered voice technology. This strategic partnership aims to create a more connected and patient-centric healthcare ecosystem.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:11 pm

RLYB

Rallybio Corporation announced the publication of Phase 1 study results for RLYB212, a monoclonal antibody aimed at preventing alloimmunization and FNAIT. The study showed promising results, and a Phase 2 trial is planned for late 2024.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:09 pm

SNAL

Snail, Inc. (NASDAQ:SNAL) announces a major Steam Publisher Sale from August 29 to September 4, 2024, offering discounts on top titles. Historically, these sales have boosted unit sales by 520% compared to non-promo periods, enhancing revenue and player engagement.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:08 pm

LUCY

Innovative Eyewear has expanded its U.S. market presence by making its Lucyd Lyte smart eyewear available on Target.com. This move is part of a partnership with the retailer Target, potentially increasing the brand's visibility and sales.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:08 pm

BAH

Booz Allen Hamilton has been awarded a task order by the U.S. Department of Homeland Security to support the Cybersecurity Infrastructure Security Agency's Continuous Diagnostics and Mitigation Defend Program. The contract has a base value of $421 million and a ceiling of $1.2 billion over three years.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:05 pm

MNSO

MINISO Group Holdings shares rose as the company announced the opening of its 200th store, indicating potential growth and expansion.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:04 pm

NVCT

Nuvectis Pharma has received Orphan Drug Designation from the FDA for its drug NXP800, aimed at treating ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. This designation could provide benefits such as market exclusivity and tax credits.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 12:02 pm

OSTX

OS Therapies has completed the treatment phase for the last patient in its AOST-2121 clinical trial of OST-HER2 for osteosarcoma. The primary endpoint analysis is expected by early Q4 2024, with topline data readout anticipated in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

August 29, 2024 | 11:58 am